| Cardiovascular

Cardiovascular Outcomes with Dulaglutide vs. Liraglutide

book_2 Source: ADA 2020 - Poster session
calendar_today Published on Medfyle: July 2020
headphones 4 min

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • The risk of cardiovascular disease (CV) increases 2- to 4-fold in patients with type 2 diabetes mellitus, lowering the life expectancy by 12 to 15 years in patients living with both conditions.
  • Cardiovascular benefits for the glucagon like peptide 1 (GLP1) agonists dulaglutide and liraglutide versus placebo are known.
  • This study compared dulaglutide and liraglutide on CV outcomes, treatment persistence/discontinuation, healthcare utilization, and costs.
  • Differences were not observed in the risk of primary and secondary composite CV outcome.
  • While differences on CV outcomes weren’t observed, greater persistence with once weekly dulaglutide over once daily liraglutide may be relevant.
Presenting Author
Read more arrow_downward Hide arrow_upward

Andy Bowe, MPH
Senior Research 

Read more arrow_downward Hide arrow_upward

A.Bowe: Employee; Self; Humana.